ES2135404T3 - Metodo de tratar la inflamacion pulmonar. - Google Patents

Metodo de tratar la inflamacion pulmonar.

Info

Publication number
ES2135404T3
ES2135404T3 ES92907905T ES92907905T ES2135404T3 ES 2135404 T3 ES2135404 T3 ES 2135404T3 ES 92907905 T ES92907905 T ES 92907905T ES 92907905 T ES92907905 T ES 92907905T ES 2135404 T3 ES2135404 T3 ES 2135404T3
Authority
ES
Spain
Prior art keywords
lung inflammation
treating lung
composition
lung
rapamicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92907905T
Other languages
English (en)
Inventor
Robert Joseph Sturm
Laurel Moore Adams
Barry Michael Weichman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2135404T3 publication Critical patent/ES2135404T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • External Artificial Organs (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)

Abstract

EL INVENTO PREVE UNA COMPOSICION FARMACEUTICA PARA PREVENIR O ANULAR LA INFLAMACION PULMONAR EN UN MAMIFERO, QUE COMPRENDE, RAPAMICINA PREPARADA POR PROCEDIMIENTOS CONOCIDOS "PER SE" Y SI SE DESEA UN PORTADOR, DILUYENTE O EXCIPIENTE ACEPTABLE FARMACEUTICAMENTE; DICHA COMPOSICION ESTA ADAPTADA PARA LA ADMINISTRACION ORAL, NASAL, PARENTERAL O INTRABRONQUIAL. COMO TAL, LA RAPAMICINA ES UTIL PARA PROPORCIONAR EL ALIVIO SINTOMATICO DE ENFERMEDADES EN LAS QUE SE PRESENTA UN COMPONENTE INFLAMATORIO PULMONAR, TALES COMO EL ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, ENFISEMA, SINDROME DE AGOTAMIENTO RESPIRATORIO AGUDO, BRONQUITIS Y SIMILARES.
ES92907905T 1991-02-22 1992-02-21 Metodo de tratar la inflamacion pulmonar. Expired - Lifetime ES2135404T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/659,782 US5080899A (en) 1991-02-22 1991-02-22 Method of treating pulmonary inflammation

Publications (1)

Publication Number Publication Date
ES2135404T3 true ES2135404T3 (es) 1999-11-01

Family

ID=24646823

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92907905T Expired - Lifetime ES2135404T3 (es) 1991-02-22 1992-02-21 Metodo de tratar la inflamacion pulmonar.

Country Status (20)

Country Link
US (1) US5080899A (es)
EP (1) EP0573584B1 (es)
JP (1) JP2673168B2 (es)
KR (1) KR100201516B1 (es)
AT (1) ATE183647T1 (es)
AU (1) AU662735B2 (es)
CA (1) CA2103571C (es)
DE (1) DE69229858T2 (es)
DK (1) DK0573584T3 (es)
ES (1) ES2135404T3 (es)
GR (1) GR3031681T3 (es)
HU (1) HUT70146A (es)
IE (1) IE920554A1 (es)
IL (1) IL100905A (es)
LV (1) LV12400B (es)
NZ (1) NZ241672A (es)
PT (1) PT100144B (es)
SG (1) SG52403A1 (es)
WO (1) WO1992014476A1 (es)
ZA (1) ZA921211B (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5358944A (en) * 1990-09-19 1994-10-25 American Home Products Corporation Rapamycin esters for treating transplantation rejection
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5262424A (en) * 1992-02-18 1993-11-16 American Home Products Corporation Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
ATE138807T1 (de) 1992-03-27 1996-06-15 American Home Prod 29-demethoxyrapamycin zur induktion der immunosuppression
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US7279561B1 (en) * 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
ES2295093T3 (es) 1993-04-23 2008-04-16 Wyeth Conjugados y anticuerpos de rapamicina.
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
DE69838338T2 (de) 1997-10-22 2008-05-21 Jens Rochester Ponikau Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
ATE411321T1 (de) 2000-09-19 2008-10-15 Wyeth Corp Wasserlösliche rapamycin-ester
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6923927B2 (en) * 2000-10-03 2005-08-02 Atrium Medical Corporation Method for forming expandable polymers having drugs or agents included therewith
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
DK1419154T3 (da) 2001-08-22 2006-01-09 Wyeth Corp Rapamycin-29-enoler
EP1419153A1 (en) 2001-08-22 2004-05-19 Wyeth Rapamycin dialdehydes
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
AU2003272489B2 (en) * 2002-09-17 2008-11-13 Wyeth Granulated formulation of the rapamycin ester CCI779
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
DE602004004520T2 (de) * 2003-04-22 2007-11-08 Wyeth Antineoplastische zusammensetzungen
US20040236279A1 (en) * 2003-05-22 2004-11-25 Atrium Medical Corp. Gaseous therapeutic agent delivery
US20040236278A1 (en) * 2003-05-22 2004-11-25 Atrium Medical Corp. Therapeutic agent delivery
US20040236410A1 (en) * 2003-05-22 2004-11-25 Atrium Medical Corp. Polymeric body formation
US20040253281A1 (en) * 2003-06-12 2004-12-16 Atrium Medical Corp. Therapeutic markings applied to tissue
PL1735321T3 (pl) * 2004-04-14 2009-04-30 Wyeth Corp Proces wytwarzania 42-estrów rapamycyny i 32-estrów FK-506 z kwasem dikarboksylowym, prekursory koniugatów rapamycyny oraz przeciwciała
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
MX2007003789A (es) * 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
WO2007059106A2 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
AU2007287809A1 (en) * 2006-08-22 2008-02-28 Novartis Ag Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders
EP2083834B1 (en) 2006-09-13 2017-06-21 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
EP2322235A1 (en) * 2006-11-20 2011-05-18 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20090274696A1 (en) * 2008-04-29 2009-11-05 Wyeth Methods for treating inflammation
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
BRPI1010655A2 (pt) * 2009-04-10 2019-09-03 Qi Haiyan novos agentes antienvelhecimento e métodos para identificá-los
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2014059295A1 (en) 2012-10-12 2014-04-17 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
MX2016010373A (es) 2014-02-11 2016-11-30 Lam Therapeutics Inc Rapamicina para el tratamiento de linfangioleiomiomatosis.
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
WO2016040570A2 (en) 2014-09-12 2016-03-17 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
RU2732908C2 (ru) 2014-10-07 2020-09-24 ЭйАй ТЕРАПЬЮТИКС, ИНК. Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии
WO2016066608A1 (en) * 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases

Also Published As

Publication number Publication date
JP2673168B2 (ja) 1997-11-05
KR930703000A (ko) 1993-11-29
IE920554A1 (en) 1992-08-26
HK1011284A1 (en) 1999-07-09
US5080899A (en) 1992-01-14
LV12400A (lv) 1999-12-20
PT100144A (pt) 1993-08-31
DE69229858T2 (de) 1999-12-09
PT100144B (pt) 1999-06-30
IL100905A (en) 1995-11-27
DK0573584T3 (da) 1999-12-13
EP0573584A4 (es) 1994-02-16
IL100905A0 (en) 1992-11-15
HUT70146A (en) 1995-09-28
ATE183647T1 (de) 1999-09-15
ZA921211B (en) 1993-08-19
AU662735B2 (en) 1995-09-14
NZ241672A (en) 1997-06-24
LV12400B (en) 2000-07-20
JPH06504790A (ja) 1994-06-02
WO1992014476A1 (en) 1992-09-03
DE69229858D1 (de) 1999-09-30
EP0573584A1 (en) 1993-12-15
AU1535692A (en) 1992-09-15
CA2103571A1 (en) 1992-08-23
SG52403A1 (en) 1998-09-28
GR3031681T3 (en) 2000-02-29
KR100201516B1 (ko) 1999-06-15
EP0573584B1 (en) 1999-08-25
CA2103571C (en) 2003-04-29

Similar Documents

Publication Publication Date Title
ES2135404T3 (es) Metodo de tratar la inflamacion pulmonar.
AU2001295760A1 (en) Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
Camus et al. The lung in inflammatory bowel disease
WO2002043765A3 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
NO20024708D0 (no) Behandling av respiratoriske sykdommer
DE60027463D1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
BRPI0517891A (pt) composições compreendendo azelastina e métodos de uso das mesmas
FI933761A0 (fi) Kompositioner och foerfaranden foer lokal administrering av farmaceutiskt aktiva aemnen
CO5140098A1 (es) Combinaciones de un agonista de betra-2 y un esteroide, su uso para tratamiento de enfermedades inflamatorias u obstructivas de las vias aereas
CA2474479A1 (en) Composition for inhalation
US20250188082A1 (en) Use of Hypoxanthine Compound In Preparation of Drug For Treating Pulmonary Fibrosis
RU2006132040A (ru) Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
CA2726872C (en) Compositions for the treatment of disorders of the upper respiratory tract and influenza syndromes
DE69928806D1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
CA2443235A1 (en) Pharmaceutical compositions comprising ascomycin
US8017588B2 (en) Clarithromycin or salt thereof for use in the treatment or prevention of pulmonary disease induced by destruction of pulmonary alveoli
US7405241B2 (en) Use of N2O in the treatment of post-ischemic brain cell deterioration
CA2648751A1 (en) Use of aminapthone for the preparation of a medicament for treating arteriopathies
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
WO2006030322A3 (en) Use of fla vone/fla vanone derivatives fn the treatment or prevention of respiratory conditions
CN115554286A (zh) 咖啡酸衍生物在制备治疗慢性阻塞性肺病药物中的应用
RU2464017C2 (ru) Способ лечения хронической обструктивной болезни легких с бронхоэктазами
CN108030786A (zh) 水线草乙素在制备治疗慢性阻塞性肺疾病的药物中的应用
WO2024192149A3 (en) Method of treating enterovirus in chronic obstructive pulmonary disease patients
Siler et al. Tolerability and efficacy of revefenacin when administered with formoterol via nebulization

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 573584

Country of ref document: ES